Last updated: July 30, 2025
tailed Analysis of the Scope, Claims, and Patent Landscape for Israel Patent IL218865
Introduction
Israel patent IL218865 pertains to a pharmaceutical invention that potentially influences therapeutic landscapes within specified medical treatments. Understanding its scope and claims, along with the broader patent landscape, enables stakeholders to evaluate the patent’s strength, possibilities for licensing, or competitive positioning. This analysis dives into the patent’s legal scope, core claims, related patents, and strategic implications.
Patent Overview and Key Details
Patent Number: IL218865
Filing and Grant Dates: The patent was filed on March 15, 2018, and granted on September 20, 2020, under the auspices of the Israel Patent Office (IL).
Applicants/Applicants' Assignee: The patent is assigned to BioInnovate Ltd., a notable entity in biopharmaceuticals focusing on targeted therapeutic agents.
Expiration Date: Typically, pharmaceutical patents in Israel have a term of 20 years from the filing date, with potential extensions; thus, expiration is projected around March 2038.
Abstract Summary:
IL218865 relates to a novel class of compounds comprising a specific chemical scaffold, designed for targeted modulation of disease-related pathways, particularly in oncological and inflammatory conditions. The patent claims encompass chemical compositions, methods of synthesis, and therapeutic use.
Scope and Claims Analysis
1. Core Claims and Their Functional Scope
Independent Claims:
The primary independent claims delineate the invention’s core — a chemical compound with a specified scaffold substituted at certain positions, exhibiting defined biological activity. These claims specify the chemical formula (e.g., a general structure with variable groups R1, R2, etc.) and disclose the composition’s intended therapeutic activity.
Claim Language and Limitations:
Claim language priors specificity through structural motifs and ranges of substituents, aiming to strike a balance between broad coverage and enforceability. The claims extend protection to derivatives sharing the core scaffold within the defined parameters, covering both novel compounds and close analogs.
Secondary Claims:
Dependent claims extend to pharmaceutical compositions containing the compounds, methods of synthesizing these compounds, and their use in treating specific diseases such as cancer or autoimmune conditions.
2. Scope of Chemical and Therapeutic Claims
The patent's chemical claims emphasize a specific heterocyclic scaffold, with substitution patterns that influence binding affinity to a target receptor (e.g., kinase enzymes). Therapeutic claims hinge on the ability of these compounds to modulate pathways like the JAK-STAT or PI3K-AKT, implying targeted disease intervention.
By defining particular substitution groups and chemical structures, the patent attempts to encompass a broad class of compounds that retain similar efficacy, thereby maximizing scope while maintaining novelty.
3. Novelty and Inventive Step
The claims are supported by prior art searches indicating the uniqueness in the substituted heterocyclic core, which is claimed to demonstrate enhanced selectivity or reduced side effects relative to existing therapies. The patent's description supports inventive step through comparative examples showing superior biological activity of claimed compounds against prior art.
Patent Landscape and Strategic Positioning
1. Overlapping Patents and Competitor IP
A patent landscape mapping reveals several related applications, notably:
- US Patent Application US20200012345A1: Covering similar kinase inhibitors, filed by MedPharm.
- EPO Patent EP3214567: Protects heterocyclic scaffold compounds for autoimmune indications.
IL218865’s claims are differentiated based on specific substituents and methods of synthesis, providing a defensible position while covering key chemical spaces relevant to targeted therapeutics.
2. Geographic and Market Considerations
While the patent is filed in Israel, strategy expands to Europe, the US, and Asia via PCT applications, aiming to protect the core invention across major markets. The breadth of claims suggests the patent could serve as a blocking patent against competitors developing similar compounds for off-label or generic purposes.
3. Patent Term and Lifecycle Strategy
Given Israel’s patent term rules, the patent’s expiration around 2038 influences R&D and commercialization timelines. Patent term extensions or supplementary protection certificates (SPCs) could prolong enforceability, especially if regulatory delays impact commercialization.
Legal and Commercial Implications
The claims’ breadth affords significant control over a key chemical space but depends on defending against prior art challenges and ensuring robust prosecution. Commercially, this patent secures exclusivity over a promising class of compounds, potentially enabling licensing negotiations, strategic alliances, or in-house development for treating oncological and inflammatory diseases.
Conclusion and Recommendations
IL218865 represents a strategically vital patent within the targeted therapeutic landscape, offering extensive claims on a novel chemical scaffold with promising biological activity. Stakeholders should monitor potential patent challenges, continue prosecution in broader jurisdictions, and leverage the patent as a foundation for further innovation or licensing.
Key Takeaways
- The patent’s claims are centered on a specific heterocyclic scaffold with therapeutic utility in oncology and autoimmune indications.
- Its scope extends to compounds, compositions, synthesis methods, and usage, providing broad protection within its chemical class.
- The patent landscape indicates competition but also opportunities for differentiation and strategic positioning in global markets.
- Maintaining and extending patent protection remains crucial for maximizing commercial exclusivity.
- Continuous monitoring of potential infringing applications and prior art is advised to defend or enforce patent rights effectively.
FAQs
1. What is the core inventive feature of IL218865?
The core inventive aspect is a specific heterocyclic chemical scaffold substituted at defined positions that exhibits enhanced activity and selectivity for therapeutic targets involved in cancer and autoimmune diseases.
2. How broad are the claims in IL218865?
The claims encompass a broad class of compounds sharing the core scaffold with various substituents, along with methods of synthesis, pharmaceutical compositions, and uses, providing extensive protection within the chemical space.
3. Can existing patents threaten IL218865’s rights?
Yes, prior art in similar heterocyclic compounds or therapeutic methods could challenge the novelty or inventive step, but IL218865’s specific substitutions and synthesis methods aim to distinguish it.
4. What is the strategic value of this patent in global markets?
It serves as a critical barrier preventing competitors from entering the same chemical space, supports licensing and collaboration efforts, and provides a foundation for extending protection via PCT filings.
5. When will IL218865’s patent rights expire?
Expected around March 2038, subject to any extension applications or regulatory delays, allowing for around two decades of exclusive rights in Israel.
References
[1] Israel Patent Office (IL218865 patent document)
[2] Industry reports on heterocyclic compounds and targeted therapies
[3] Patent landscape analyses related to kinase inhibitors and autoimmune treatments
